The Cadex Genomics mission and passion is to improve the lives of cancer patients. They have developed a novel, blood-based assays for patients with cancer. Over the past several years they have been working diligently to bring their first product to patients and the physicians who serve these patients. They are currently developing a new product called Alibrex, which is a blood-based assay that allows physicians to detect, in real-time, if the disease of their stage IV cancer patients is progressing.
Alibrex is currently at the clinical stage and will be available commercially in 2023. The team members have successful track records commercializing molecular diagnostics for oncology at companies including Genomic Health (now part of Exact Sciences), Castle Biosciences and Veracyte. Science and clinical team members are affiliated with the University of New Orleans, Tulane University and the University of California at San Francisco (UCSF). Independent board directors include the Chief Legal and Regulatory Officer for 23 and Me.
Torque3 is developing a neurorehabilitation solution that has shown in early testing to result in significantly better recovery outcomes. A wealth of research over...
David Yakobi, MD is a Board Certified Cardiac Surgeon and specialist in Cardiology, Intensive Care, Emergency Medicine, Hemodynamics, and Physiology. Dr. Yakobi has vast...
TMI is developing the POINT-GUARD, the first and only cerebral embolic protection device with dynamic Double-Edge Sealing. The seal adapts and conforms to complex...
